Market capitalization | $52.81m |
Enterprise Value | $-69.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.73 |
P/B ratio (TTM) P/B ratio | 0.44 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-79.57m |
Free Cash Flow (TTM) Free Cash Flow | $-94.87m |
Cash position | $121.85m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast AlloVir Inc:
1 Analyst has issued a forecast AlloVir Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.14 -0.14 |
-
|
|
EBITDA | -79 -79 |
54%
54%
|
EBIT (Operating Income) EBIT | -80 -80 |
55%
55%
|
Net Profit | -100 -100 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.
Head office | United States |
CEO | Vikas Sinha |
Employees | 112 |
Founded | 2013 |
Website | www.allovir.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.